Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -21.60% is 87% below its 5-year average of -11.55%, around the middle of its 5-year range (-41.83%–12.53%).
6.41% above its 12-month average of -23.08%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -23.68%.
OPERATING MARGIN
-21.60%
OPERATING MARGIN AVG TTM
-23.08%
OPERATING MARGIN AVG 3Y
-17.60%
OPERATING MARGIN AVG 5Y
-11.55%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.41%
CURRENT VS 3Y AVG
-22.75%
CURRENT VS 5Y AVG
-86.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 554 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$772.27M
Operating Margin
-21.60%
TTM Avg
-23.08%
3Y Avg
-17.60%
5Y Avg
-11.55%
Market Cap
$772.90M
Operating Margin
-98.21%
TTM Avg
-366.21%
3Y Avg
-21871.64%
5Y Avg
-19485.10%
Market Cap
$773.03M
Operating Margin
-29.28%
TTM Avg
-127.46%
3Y Avg
-26333.62%
5Y Avg
-23986.43%
Market Cap
$777.55M
Operating Margin
-4974.74%
TTM Avg
-2487.37%
3Y Avg
-2487.37%
5Y Avg
-2487.37%
Market Cap
$759.16M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$788.35M
Operating Margin
9.00%
TTM Avg
7.11%
3Y Avg
-27.53%
5Y Avg
-16.39%
Market Cap
$796.60M
Operating Margin
-0.31%
TTM Avg
6.92%
3Y Avg
0.39%
5Y Avg
2.91%
Market Cap
$752.12M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-6934.80%
5Y Avg
-9894.67%
Market Cap
$808.29M
Operating Margin
9.86%
TTM Avg
12.61%
3Y Avg
-6.26%
5Y Avg
-239.99%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $772.27M | -21.60% | -23.08% | -17.60% | -11.55% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | -98.21% | -366.21% | -21871.64% | -19485.10% |
| Geron Corporation (GERN)vs › | $773.03M | -29.28% | -127.46% | -26333.62% | -23986.43% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $777.55M | -4974.74% | -2487.37% | -2487.37% | -2487.37% |
| Design Therapeutics, Inc. (DSGN)vs › | $759.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mesa Laboratories, Inc. (MLAB)vs › | $788.35M | 9.00% | 7.11% | -27.53% | -16.39% |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | -0.31% | 6.92% | 0.39% | 2.91% |
| Candel Therapeutics, Inc. (CADL)vs › | $752.12M | 0.00% | 0.00% | -6934.80% | -9894.67% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | 9.86% | 12.61% | -6.26% | -239.99% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $734.60M | -123601.69% | -69568.65% | -35191.57% | -23714.64% |
Gross Margin
53.2%
Operating Margin
-21.6%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -23.68% |
| 2026-03-31 | -41.83% |
| 2025-12-31 | -9.00% |
| 2025-09-30 | -17.58% |
| 2025-06-30 | -23.30% |
| 2025-03-31 | -36.12% |
| 2024-12-31 | 5.20% |
| 2024-09-30 | -8.25% |
| 2024-06-30 | -18.29% |
| 2024-03-31 | -23.93% |
| 2023-12-31 | -0.24% |
| 2023-09-30 | -13.38% |
| 2023-06-30 | -18.37% |
| 2023-03-31 | -32.79% |
| 2022-12-31 | 0.17% |
| 2022-09-30 | 3.36% |
| 2022-06-30 | -2.22% |
| 2022-03-31 | -6.72% |
| 2021-12-31 | 3.39% |
| 2021-09-30 | 8.43% |
| 2021-06-30 | 12.53% |
| 2021-03-31 | 4.66% |
| 2020-12-31 | 25.72% |
| 2020-09-30 | 26.74% |
| 2020-06-30 | -1.14% |
| 2020-03-31 | -3.95% |
